Evaluate Persistence of Immune Response of GSK Biologicals' TWINRIX Vaccine Administered According to 0,6 Month Schedule Versus TWINRIX JUNIOR Administered According to 0,1,6 Month Schedule, in Subjects Aged 12-15 Years at Time of First Vaccine Dose.

Trial Profile

Evaluate Persistence of Immune Response of GSK Biologicals' TWINRIX Vaccine Administered According to 0,6 Month Schedule Versus TWINRIX JUNIOR Administered According to 0,1,6 Month Schedule, in Subjects Aged 12-15 Years at Time of First Vaccine Dose.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Hepatitis A-hepatitis B vaccine (Primary)
  • Indications Hepatitis A; Hepatitis B
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 27 Oct 2008 Actual end date changed Jul 2008 to Jun 2004 as reported by ClinicalTrials.gov.
    • 09 Sep 2008 Additional trial identifiers 100566,100567,100568,100569,100570 added as reported by ClinicalTrials.gov.
    • 09 Sep 2008 Primary endpoint identified as antibody level as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top